This application seeks support for an interdisciplinary postdoctoral research training program which is designed to prepare clinicians for a full-time career in cancer research and education. Support for nine postdoctoral research fellows is requested. This training grant which, for 21 of its 25 years, provided a broad training in cancer biology and therapy, is focused on the studies of genetic and epigenetic alterations in cancer with the ultimate goal to use these molecular changes, which are unique to cancer cells as new indicators for detection of cancer cells and specific targets for therapy. The primary purpose of this training grant is to train the physician-scientist in basic and translational cancer research. This training grant is offered as two-year or more training program and has been a major support vehicle to provide an intensive research experience for physician trainees. The majority of the trainees enter this program via the Cancer Center Medical Oncology Fellowship Program but spend all but the first clinical year (which is funded from other resources) in full-time laboratory research. Only the most qualified and outstanding applicants are selected for these few slots. The training faculty who serve as mentors for individual trainees in this program are acknowledged leaders in their field. Examples include, but are not limited to, Drs. Volgestein and Kinzler (genetic changes in progression of cancer), Baylin and Herman (role of methylation in progression of cancer), Isaacs and Sukumar (molecular biology of prostate and breast cancer) and Pardoll and Jaffee (novel approaches to cancer vaccines). In addition a close interaction between the faculty of this training program with other graduate and postgraduate training programs in basic science in the School of Medicine provides comprehensive exposure to basic aspects of cancer biology. As part of their training curriculum, trainees are required to complete two courses in the basic aspects of cancer biology and therapy, and actively participate in ongoing seminars, including a presentation of their research at Fellows Research Day. Mentors monitor the trainee's research progress while continuously emphasizing ethical and responsible conduct of research.

Public Health Relevance

The primary purpose of this training grant is to train the physician-scientist in basic and translational cancer research. This training grant is focused on the studies of genetic and epigenetic alterations in cancer with the ultimate goal to use these molecular changes, which are unique to cancer cells as new indicators for detection of cancer cells and specific targets for therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
3T32CA009071-34S1
Application #
8871891
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
1979-09-15
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
34
Fiscal Year
2014
Total Cost
$45,674
Indirect Cost
$2,198
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Deshwar, Amar B; Sugar, Elizabeth; Torto, Deirdre et al. (2018) Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Ann Pancreat Cancer 1:
Saung, May Tun; Zheng, Lei (2017) Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 39:2125-2134
Yarchoan, Mark; Johnson 3rd, Burles A; Lutz, Eric R et al. (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17:209-222
Yarchoan, Mark; Myzak, Melinda C; Johnson 3rd, Burles A et al. (2017) Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget 8:44073-44081
Imus, Philip H; Blackford, Amanda L; Bettinotti, Maria et al. (2017) Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant 23:1887-1894
Johnson 3rd, Burles A; Yarchoan, Mark; Lee, Valerie et al. (2017) Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res 23:1656-1669
Diehl, Adam; Yarchoan, Mark; Hopkins, Alex et al. (2017) Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8:114268-114280
Shroff, Rachna T; Yarchoan, Mark; O'Connor, Ashley et al. (2017) The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer 116:1402-1407

Showing the most recent 10 out of 178 publications